PUBLIC COMPANY
save$MSLESatellos Bioscience Inc.
$MSLEToronto, Ontario, CAupdated 5mo ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Preclinical1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Satellos' new Duchenne study endpoint; Amgen's Repatha cuts heart attack riskPlus, news about MetaVia, Agios Pharmaceuticals and Inovio. Satellos Bioscience changes Duchenne study primary endpoint: The company is studying a small-molecule drug called forazapadin aimed at he…endpoints · 15d ago
- Capricor CEO won’t rule out legal action against FDA after negative adcommAfter an FDA advisory committee voted 9-3 on Wednesday against recommending Capricor Therapeutics’ Duchenne muscular dystrophy cardiomyopathy drug for approval, stakeholders allege an “ulterior mot…biospace · 3mo ago
- Satellos gives early look at Duchenne pill in adults ahead of key data in childrenSatellos Bioscience is building its case for a Duchenne muscular dystrophy pill with data in adult patients ahead of a potentially pivotal readout in children later this year. The Canadian biotech’…endpoints · 4mo ago
Data sources
last refreshed 22m ago
Found something off?
comments(0)
5-min edit window · permanent after that